The Mayo Protein Core (MPC) Shared Resource was reorganized as the PROTEIN CHEMISTRY AND PROTEOMICS (PCP) Facility in January 2002. The facility has been an important shared resource of the Mayo Clinic Cancer Center (MCCC) since 1992. In the past decade, the PCP shared resource has continued its rapid growth and expansion of core services, and has been an essential resource to MCCC members by its support of a broad diversity of program projects in cancer research. Usage of the resource has grown substantially from 21 members in 1992, to more than 70 current members in 2002. The reorganization of the MPC facility into the PCP shared resource has provided for the development of new services in mass spectrometry to support proteomics based investigations. These services include protein identification by MALDI-TOF mass spectrometry, MS/MS tandem mass spectrometry, and Fourier Transform Ion Cyclotron Resonance (FT-ICR) mass spectrometry. In addition, the PCP resource also provides basic services in protein chemistry, which include solid phase peptide synthesis, protein purification and quantitation, amino acid analysis, chemical protein sequencing, 2-D polyacrylamide gel electrophoresis, and protein molecular modeling. A list of current services provided to MCCC members are:(1) Solid phase peptide synthesis by Fmoc methods; (2) Synthesis of peptidelprotein specific immunogens on KLH or BSA carrier proteins;(3) Edman N-terminal and C-terminal protein sequencing; (4) Quantitative amino acid analysis; (5) Protein purification by reverse phase HPLC and FPLC; (6) Computer-aided analysis of protein sequences for synthetic peptide design; (7) Protein molecular modeling; (8) 1-D and 2-D PAGE of complex protein mixtures; (9) Automated protein digestion and robotic handling of digests for mass spectrometry analysis; (10) Protein identification by MALDI-TOF peptide mass fingerprinting, and (11) Protein identification by peptide sequencing using Ion- Trap LC-MS/MS mass spectrometry. In addition to the services listed above, the continued development of methods in protein mass mappinc by 2D-LC FT-ICR mass spectrometry and the analysis of proteins from cells and biological samples using protein microarrays will also be conducted in the resource.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-30
Application #
6989933
Study Section
Subcommittee G - Education (NCI)
Project Start
2004-09-15
Project End
2009-02-28
Budget Start
2004-09-15
Budget End
2005-02-28
Support Year
30
Fiscal Year
2004
Total Cost
$134,124
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547

Showing the most recent 10 out of 1129 publications